EDINBURGH, Scotland , May 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Kuick Research has recognized the Company as a key player in the gamma-delta T cell therapy market. In April, Kuick Research released its " Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028 " which focuses on the therapy, the companies in the sector, updates on the current drugs in research & development, and the size of the sector.

Digital Brands Group, Inc. ("DBG") (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands, today announces its initial 2022 revenue guidance of $37.5 million to $42.5 million, an increase of 350% from 2021 revenue expectations. Additionally, the Company forecasts positive EBITDA for 2022, as it leverages its shared services platform

Bethlehem, PA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vinco Ventures, Inc. (NASDAQ: BBIG) a leader in selective acquisitions leveraging new market opportunities by utilizing the B.I.G. Strategy: Buy. Innovate. Grow. today announce the company’s 2021 Annual Proxy details and provides a corporate update in a new investor presentation.

 Tel Aviv, Sept. 02, 2021  -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: “APOP”), announced the first ApoGraft TM transplantation in a Leukemia patient in the Company’s clinical trial at Washington University in the U.S. ApoGraft TM is a product based on the Company’s cell selection technology designed to optimize immune therapy, in this application - prevent graft-versus-host disease (GVHD) following bone marrow transplantation.

Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraft TM development will be pursued by EnCellX, the privately held U.S. based company that is acquiring Cellect’s proprietary technology concurrently with such merger. The trial will enroll 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation (BMT). EnCellX, led by Founder and CEO Adi Mohanty, is raising funds from leading healthcare institutional investors to expedite and expand clinical development.

SGOCO Group (NASDAQ:SGOC) is a conglomerate with four primary businesses — virtual reality, energy saving technology, mortgage lending and real estate investment. Based in China, the multihyphenate company was thrust into the spotlight in July thanks to a two-session performance that saw SGOC stock soar 675%.